2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-173486
    BuChE-IN-21 98%
    BuChE-IN-21 (compound SXF3) is a potent and selective BuChE inhibitor. BuChE-IN-21 inhibits eqBuChE and hBuChE with IC50s of 0.05 and 0.04 μM, respectively. BuChE-IN-21 has high anti-inflammatory activity.
    BuChE-IN-21
  • HY-173509
    ATX inhibitor 27 2023027-81-6 98%
    ATX inhibitor 27 (Compound 31) is an ATX inhibitor. The IC50 values of ATX inhibitor 27 against human autotaxin (hATX) and lysophosphatidylcholine (LPC) are 13 nM and 23 nM, respectively. ATX inhibitor 27 reduces LPA levels in vivo by inhibiting ATX enzyme. ATX inhibitor 27 can be used in the study of ATX-LPA-related diseases such as inflammation, neurodegenerative diseases and cancer.
    ATX inhibitor 27
  • HY-173513
    IDO1/TDO-IN-8 98%
    IDO1/TDO-IN-8 (Compound CZ-17) is a dual IDO1 and TDO inhibitor that can penetrate the blood-brain barrier, with EC50 values of 0.33 μM and 1.78 μM, respectively. IDO1/TDO-IN-8 reduces the kynurenine/tryptophan ratio by regulating the kynurenine pathway of tryptophan metabolism. IDO1/TDO-IN-8 has a neuroprotective effect and can alleviate motor dysfunction and improve depressive behavior. IDO1/TDO-IN-8 can be used in the study of Parkinson's disease combined with depression.
    IDO1/TDO-IN-8
  • HY-173516
    CCR5-IN-1 98%
    CCR5-IN-1 (compound 3ad) is a selective allosteric CCR5 inhibitor with an IC50 of 1.09 μM. CCR5-IN-1 can be used in the study of cardiovascular, central nervous system, immune system, and infectious diseases.
    CCR5-IN-1
  • HY-173517
    NHE-1-IN-2 98%
    NHE-1-IN-2 (compound 7g) is a potent NHE-1 inhibitor with an IC50 of 0.78 μM. NHE-1-IN-2 alleviates left ventricular systolic dysfunction in mice model of heart failure.
    NHE-1-IN-2
  • HY-17355S
    Pramipexole-d7 dihydrochloride 98%
    Pramipexole-d7 dihydrochloride is the deuterium labeled Pramipexole dihydrochloride. Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS).
    Pramipexole-d7 dihydrochloride
  • HY-173574
    RIPK1-IN-31 2857845-45-3
    RIPK1-IN-31 (Compound 36) is a selective allosteric modulator of RIPK1 (receptor-interacting protein kinase 1) with an IC50 value of 16 nM. RIPK1-IN-31 is promising for research of infectious, autoimmune, and neurodegenerative diseases.
    RIPK1-IN-31
  • HY-17360R
    Tiotropium Bromide (Standard) 136310-93-5
    Tiotropium (Bromide) (Standard) is the analytical standard of Tiotropium (Bromide). This product is intended for research and analytical applications. Tiotropium Bromide (BA679 BR) is a muscarinic acetylcholine receptor (mAChR) antagonist that blocks the binding of the acetylcholine ligand and subsequent opening of the ligand-gated ion channel.
    Tiotropium Bromide (Standard)
  • HY-173615
    KTD-092 98%
    KTD-092 is a hit for DYRK1A inhibition, with an IC50 of 22 nM for human DYRK1A. KTD-092 can be used in the research for Down syndrome (DS), Alzheimer's disease (AD), autism spectrum disorder (ASD), diabetes and other neurodegenerative diseases.
    KTD-092
  • HY-173616
    GABAA receptor modulator-8 2889382-34-5 98%
    GABAA receptor modulator-8 (10c) is a blood-brain barrier penetrated, selective and positive modulator of GABAA receptor, with excellent antiepileptic activity.
    GABAA receptor modulator-8
  • HY-173621
    Aβ1–42 aggregation inhibitor 3 32527-84-7 98%
    Aβ1–42 aggregation inhibitor 3 (Compound 3b) is an acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitor (IC50 values are 1.634 and 0.0285 μM, respectively). Aβ1–42 aggregation inhibitor 3 can inhibit the aggregation of Aβ1-42. Aβ1–42 aggregation inhibitor can be used in Alzheimer's disease (AD) research.
    Aβ1–42 aggregation inhibitor 3
  • HY-173623
    EU 1622-240 3057728-22-7 98%
    EU 1622-240 is a biased positive allosteric modulator of GluN2B, GluN2C, and GluN2D, with EC50s of 0.57, 0.82, 1.1 μM respectively. EU 1622-240 has good physicochemical properties, in vitro stability, and permeability.
    EU 1622-240
  • HY-17366R
    Clozapine N-oxide (Standard) 34233-69-7
    Clozapine N-oxide (Standard) is the analytical standard of Clozapine N-oxide. This product is intended for research and analytical applications. Clozapine N-oxide is a major metabolite of Clozapine and a human muscarinic designer receptors (DREADDs) agonist. Clozapine N-oxide activates the DREADD receptor hM3Dq and hM4Di. Clozapine N-oxide can cross the blood-brain barrier[1][2][3][4]. Clozapine is a potent dopamine antagonist and also a potent and selective muscarinic M4 receptor (EC50=11 nM) agonist[5][6].
    Clozapine N-oxide (Standard)
  • HY-17380R
    (S)-Timolol maleate (Standard) 26921-17-5
    (S)-Timolol (maleate) (Standard) is the analytical standard of (S)-Timolol (maleate). This product is intended for research and analytical applications. (S)-Timolol Maleate (L-714,465 Maleate) is a non-cardioselective hydrophilic β-adrenoceptor blocker. (S)-Timolol Maleate is widely used as standard medication for intraocular pressure (glaucoma) by preventing the production of aqueous humor. (S)-Timolol Maleate can be used for hypertension, angina pectoris and myocardial infarction.
    (S)-Timolol maleate (Standard)
  • HY-17380S
    (S)-Timolol-d9 maleate 98%
    (S)-Timolol-d9 (maleate) is deuterium labeled (S)-Timolol (Maleate). (S)-Timolol Maleate (L-714,465 Maleate) is a non-cardioselective hydrophilic β-adrenoceptor blocker. (S)-Timolol Maleate is widely used as standard medication for intraocular pressure (glaucoma) by preventing the production of aqueous humor. (S)-Timolol Maleate can be used for hypertension, angina pectoris and myocardial infarction.
    (S)-Timolol-d9 maleate
  • HY-17382C
    Metoclopramide dihydrochloride 2576-84-3 98%
    Metoclopramide dihydrochloride acts as a dopamine D2 antagonist and is utilized for its antiemetic properties.
    Metoclopramide dihydrochloride
  • HY-17383R
    Levomefolate calcium (Standard) 151533-22-1
    Levomefolate (calcium) (Standard) is the analytical standard of Levomefolate (calcium). This product is intended for research and analytical applications. Levomefolate (calcium) is an orally active, BBB-penetrable and active form of folic acid. Levomefolate (calcium) can be used as a food supplement for folic acid and in the research of neural tube defect diseases.
    Levomefolate calcium (Standard)
  • HY-17385S
    Atomoxetine-d5 hydrochloride 98%
    Atomoxetine-d5 (hydrochloride) is the deuterium labeled Atomoxetine hydrochloride. Atomoxetine hydrochloride is a potent and selective noradrenalin re-uptake inhibitor (Ki values are 5, 77 and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively).
    Atomoxetine-d5 hydrochloride
  • HY-17386S
    Rosiglitazone-d3 1132641-22-5 98%
    Rosiglitazone-d3 is the deuterium labeled Rosiglitazone. Rosiglitazone (BRL 49653) is a selective, orally active PPARγ agonist with EC50s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively. Rosiglitazone binds to PPARγ with a Kd of approximately 40 nM. Rosiglitazone is also an activator of TRPC5 (EC50=~30 μM) and an inhibitor of TRPM3.
    Rosiglitazone-d3
  • HY-17390B
    Loxapine hydrochloride 54810-23-0 98%
    Loxapine hydrochloride is an orally active dopamine inhibitor, 5-HT receptor antagonist and also a dibenzoxazepine anti-psychotic agent.
    Loxapine hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity